| Document |
Document Title |
|
WO/2023/212134A9 |
The disclosure provides methods for synthesis of peracetylgalactosamine-1-pentanoic acid, also called peracetylated D-galactosamine C5 linker or GalNAc C5 linker, using a vegetal source as a starting material, such as vegetal-sourced D-g...
|
|
WO/2024/068511A1 |
A compound has the general Formula (I) (e.g., Floridiolic acid, 6-[(acetyloxy)methyl]-3,5- dihydroxy-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl (4aS,5R,6S,8aR)-5-[(3Z)-5-hydroxy-3- (hydroxymethyl)pent-3-en-l-yl]-5,6,8a-trimethyl-3,4,4a,...
|
|
WO/2024/064634A1 |
This present invention relates to modified sophorolipid molecules for enhancing the dispersion of particulate substances, including nanoparticles. In certain embodiments, the compositions and methods can be used for improved dispersion i...
|
|
WO/2024/058253A1 |
The objective of the present invention is to provide a composition comprising an LPS of a Gram-negative bacterium having a predetermined structure or a predetermined activity. According to the present invention, provided is a composition...
|
|
WO/2024/050640A1 |
The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-asso...
|
|
WO/2024/038195A1 |
The present invention relates to new specific 2'-fucosyllactose propionate compounds, to a new and improved synthesis of specific 2'-fucosyllactose propionates as well their use. Propionate compounds are very useful compounds.
|
|
WO/2024/005723A1 |
The present invention relates to a novel granulated or powdered brown natural slow sugar and a process for manufacturing the same based on esterification. The product obtained, i.e. the novel brown natural slow sugar, can be consumed by ...
|
|
WO/2024/005722A1 |
The present invention relates to a novel granulated or powdered white natural slow sugar and to a process for manufacturing same based on esterification. The product obtained, i.e. the novel white natural slow sugar, can be consumed by a...
|
|
WO/2023/221758A1 |
The present invention relates to a crystal of lacto-N-triaose, and belongs to the technical field of separation and purification. The technical solution of the present invention is a crystal form B of LNTII, which crystal form has charac...
|
|
WO/2023/222659A1 |
Provided herein are compounds that function as surfactants and/or excipients, methods of producing such compounds, methods of using such compounds and compositions comprising such compounds preferably in combination with one or more addi...
|
|
WO/2023/216890A1 |
The invention provides a lacto-N-triose II crystal form A and a preparation method therefor. The powder X-ray diffraction pattern of the crystal form has characteristic diffraction peaks at diffraction angles (2θ ± 0.2°) of 4.80, 8.32...
|
|
WO/2023/212741A1 |
Highly pure, highly homogeneous ganglioside compositions are provided in addition to methods of making and using these compositions. An exemplary ganglioside composition is a GM1 composition.
|
|
WO/2023/197278A1 |
Disclosed is a solvent-free synthesis method for a sucrose ester having high monoester content. The method comprises the following steps: (1) mixing sucrose, a higher fatty acid ester, and a higher fatty acid salt, and preheating at 70-9...
|
|
WO/2023/197791A1 |
The present invention relates to a cyclic carbonate nucleoside compound as represented by formula (I), and a pharmaceutically acceptable salt, a crystalline hydrate, a solvate or a tautomer thereof, and further disclosed are a pharmaceut...
|
|
WO/2023/175536A1 |
Provided herein are compounds that contain one or more lipophilic moieties and can be used to prepare one or more lipophilic monomers. Also provided herein are lipophilic monomers that can be conjugated to one or more positions on at lea...
|
|
WO/2023/178017A1 |
Compositions of de-acylated carbohydrate compounds and methods of making them are provided. The methods can be designed to produce the desired products under conditions of moderate temperature, moderate pH, and without the use of harsh s...
|
|
WO/2023/172606A1 |
The present invention provides modified sophorolipids comprising taurine for improved foaming performance. The present invention also provides compositions comprising the modified sophorolipids fonnulated for cosmetics and personal care ...
|
|
WO/2023/168329A2 |
Disclosed are novel prodrugs derived from nicotinic acid and pharmaceutical compositions thereof which may be used to treat or prevent a variety of medical disorders, which may be characterized by mitochondrial dysfunction. The compounds...
|
|
WO/2023/150667A2 |
The present disclosure provides a compound of Formula I: A-Rl-A' wherein A and A' are independently H or [Formula I], wherein A, A', and R1 are as described herein. Also provided are methods of making the compounds described herein, and ...
|
|
WO/2023/107583A1 |
An improved agent and treatment method for a broad variety of diseases in both animals and humans is disclosed. The agent is an inventive composition comprising a bacterial-based culture. Particularly, the inventive composition disclosed...
|
|
WO/2023/099297A1 |
The present invention relates to new specific butyrate compounds to a new and improved synthesis of specific butyrates as well their use. Butyrate compounds are very useful compounds.
|
|
WO/2023/092188A1 |
Compounds and compositions comprising said compounds, which have agrichemical activity such as herbicides, insecticides, fungicides and plant growth regulators; and methods for the use of said compounds.
|
|
WO/2023/089562A1 |
Methods of treating materials, such as cellulose-based materials, to provide barrier properties like water resistance and lipid resistance (OGR), separately or in combination, and particularly at high temperatures, by using bio-based coa...
|
|
WO/2023/083570A1 |
The present invention relates to polyol-derived compounds and processes preparing the same.
|
|
WO/2023/070223A1 |
The invention provides for a vaccine against S. suis serotype 2. The vaccine comprises chemically synthesized fragments and thus may be made widely commercially available. The vaccine is used in the livestock production and may be adapte...
|
|
WO/2023/069858A1 |
Methods for controlled synthesis and chemical recycling of stereoregular polysaccharides via polymerization of biomass-derived anhydrosugars are provided. The anhydrosugars react with an initiator in the presence of a synergy of a cataly...
|
|
WO/2023/002354A1 |
The present invention relates to new synthetic molecules with agonist activity of human Toll-like Receptor 4 (TLR4), compositions comprising them and uses thereof for the treatment of diseases in which it is useful to induce or increase ...
|
|
WO/2023/001004A1 |
The present invention relates to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine, and in particular to a mannose derivative and an application thereof. The mannose derivative is an isonitrile-containin...
|
|
WO/2022/268239A1 |
Provided herein are carbohydrate derivatives of general formula (I) bearing a trans-cyclooctene moiety usable in covalently binding active moieties to cell surfaces in vitro and/or in vivo and their use for therapeutic or nontherapeutic ...
|
|
WO/2022/271018A1 |
The invention is in the field of medical sciences. It provides new pharmaceutical methods and preparations. The invention relates to methods for improving the pharmacokinetic, physicochemical or pharmaceutical properties of drugs by conv...
|
|
WO/2022/265964A1 |
Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 in...
|
|
WO/2022/264171A1 |
The present disclosure provides compounds of Formula I and a process of preparing the compounds of Formula I. The present disclosure further provides a compound of Formula II, Formula III, and Formula IV. The present disclosure provides ...
|
|
WO/2022/253234A1 |
The present invention relates to a crystal form I and crystal form II of the compound 2-N-4,6-di-O-tributyryl-D-glucosamine, and a preparation method therefor and the use thereof. The crystal form I and crystal form II obtained in the pr...
|
|
WO/2022/246846A1 |
Disclosed are a supported organotin catalyst and a preparation method for a sucrose-6-carboxylate. The supported organotin catalyst is prepared by coupling an organotin functional group to an inorganic carrier. The supported organotin ca...
|
|
WO/2022/233040A1 |
Disclosed in the present invention is a method for purifying sucralose-6-ethyl ester, the method comprising: a second instance of boiling with water step, involving: taking a sucralose-6-ethyl ester mother solution, which has been subjec...
|
|
WO/2022/140931A9 |
The present application provides a chlorination method for a sucrose-6-carboxylate, comprising: dissolving a solid phosgene into a first solvent to obtain a solid phosgene solution, and dissolving a sucrose-6-carboxylate into a second so...
|
|
WO/2022/215441A1 |
Provided is a novel active ingredient derived from carob and a usage therefor. The present invention is a compound represented by formula (I) or a salt thereof, or a solvate of the compound or the salt.
|
|
WO/2022/198478A1 |
Provided are a supported catalyst and a synthesis method for sucrose-6-ester. The supported catalyst is used for catalyzing a transesterification reaction of sucrose and a carboxylic ester. The catalyst comprises an active functional com...
|
|
WO/2022/174382A1 |
A production apparatus and production method for sucrose-6-ester; said apparatus comprises a tank body, a heating pipe, an annular cooling device, and a motor; the annular cooling device and the heating pipe are sequentially nested in th...
|
|
WO/2022/174381A1 |
A production apparatus for sucrose-6-ester, comprising a distillation separation tank, a reaction tank, and a condensed water collection tank. The distillation separation tank is arranged above the reaction tank and the condensed water c...
|
|
WO/2022/165803A1 |
A production apparatus and a production method for sucrose-6-ester, the apparatus comprising a tank, a rotary distillation device, and a condensing device, wherein the tank comprises a separation cavity and a reaction cavity, the condens...
|
|
WO/2022/163846A1 |
The purpose of the present invention is to provide: a novel stereoselective method for producing a cyclic dinucleotide derivative that can be used for an antibody-immunostimulator conjugate; and a production intermediate thereof. Another...
|
|
WO/2022/155814A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that comprise one or more ligand moieties for an asialoglycopr...
|
|
WO/2022/155909A1 |
Provided are a production device and production method for sucrose-6-ester. The device comprises separators and a reactor; each separator comprises an accommodation cavity and a condensation cavity which are provided closely and in commu...
|
|
WO/2022/155947A1 |
Production equipment and a production method for sucrose-6-ester, wherein the equipment comprises a housing, a film scraping device, and a base. The film scraping device is disposed on the base, and the housing covers the outer sides of ...
|
|
WO/2022/141457A1 |
The present application provides a mono-tin organic compound which is used for synthesizing sucrose-6-carboxylate. The compound is a compound represented by formula (1) below. R1, R2 and R3 each independently represent C1-C8 linear or br...
|
|
WO/2022/110017A1 |
A method for purifying sucralose-6-ethyl ester, comprising: a preparation step: obtaining an ethyl acetate saturated solution of crude sucralose-6-ethyl ester heated to a predetermined temperature; a gradient crystallization step: perfor...
|
|
WO/2022/111578A1 |
A stellate compound that has a significant anti-coronavirus spike protein targeting ability and that has a certain broad spectrum. The described class of molecule and salt thereof have at least one R(x)… basic unit, which binds at an o...
|
|
WO/2022/087107A1 |
Compositions for treating an ischemic condition in a subject may include hexosamine D-mannosamine (ManN). Methods may include administering to the subject in need thereof an effective amount of ManN. The administration may be effective t...
|
|
WO/2022/083106A1 |
The present invention relates to the field of pharmaceutical chemicals, and relates to a method for preparing a glucosamine sulfate composite salt. The method comprises: adding N-acetylglucosamine and a solvent into a reaction vessel, th...
|
